Skip to Content

Florbetaben f-18 Pregnancy and Breastfeeding Warnings

Florbetaben f-18 is also known as: Neuraceq

Florbetaben f-18 Pregnancy Warnings

This drug should be used during pregnancy only if clearly needed.

US FDA pregnancy category: C

Comments: Assess pregnancy status before administering this drug to a female of reproductive potential. All radiopharmaceuticals have a potential to cause fetal harm. The likelihood of fetal harm depends on the stage of fetal development and the magnitude of the radiopharmaceutical dose.

Animal reproduction studies have not been conducted with this drug. It is not known whether this drug can cause fetal harm when administered to a pregnant woman or if it can affect reproduction capacity. Animal reproduction studies have not been conducted with this drug.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Florbetaben f-18 Breastfeeding Warnings

Use should be avoided.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: Temporarily interrupt breastfeeding for 24 hours after exposure to florbetaben. The patient should pump and discard breast milk and use other nutrition sources (e.g. stored breast milk or infant formula) for 24 hours after the administration of this drug.

See references

References for pregnancy information

  1. "Product Information. Neuraceq (florbetaben F-18)." IBA Molecular North America Inc, Dulles, VA.

References for breastfeeding information

  1. "Product Information. Neuraceq (florbetaben F-18)." IBA Molecular North America Inc, Dulles, VA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide